InflaRx GmbH
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 2007-12-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.inflarx.com
Clinical Trials
49
Trial Phases
4 Phases
Drug Approvals
3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
- Conditions
- Chronic Urticaria, IdiopathicHidradenitisHidradenitis Suppurativa
- Interventions
- Drug: HS medium dose treatmentDrug: HS low dose treatmentDrug: HS high dose treatmentDrug: CSU high dose treatmentDrug: CSU non responders IgE - high dose treatmentDrug: CSU lower dose treatment
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT06555328
- Locations
- 🇺🇸
First OC Dermatology Research Inc., Fountain Valley, California, United States
🇺🇸Ziaderm Research LLC, North Miami Beach, Florida, United States
🇺🇸ForCare Clinical Research, Tampa, Florida, United States
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 90
- Registration Number
- NCT05964413
- Locations
- 🇺🇸
Aby´s New Generation Research, Inc, Hialeah, Florida, United States
🇺🇸Dermatology/University of Miami Hospital, Miami, Florida, United States
🇺🇸University of Central Florida College of Medicine, Orlando, Florida, United States
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
- Conditions
- SCC - Squamous Cell Carcinoma of Skin
- Interventions
- Drug: Vilobelimab + pembrolizumab combination therapy
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT04812535
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
- Conditions
- Severe COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 399
- Registration Number
- NCT04333420
- Locations
- 🇧🇪
InflaRx Site #1107, Aalst, Belgium
🇧🇪InflaRx Site #1102, Brussels, Belgium
🇧🇪InflaRx Site #1104, Leuven, Belgium
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- InflaRx GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT03971643
- Locations
- 🇺🇸
InflaRx Site #07, Sacramento, California, United States
🇺🇸InflaRx Site #08, Miami, Florida, United States
🇺🇸InflaRx Site #03, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- Next